Sirius Therapeutics Secures Nearly $100 Million in Financing to Advance siRNA Pipeline and Submits IPO Application

Recently, Sirius Therapeutics (SHANGHAI) Co., Ltd. (referred to as: Sirius Therapeutics) announcedCompleted a $60 million Series B financing round，To advance the clinical development of its siRNA novel therapy pipeline and the iterative innovation of next-generation nucleic acid molecule delivery technology.This round of financing was led by Shanghai Hankang Private Equity Fund Management Co., Ltd., with participation from Delos Capital, and existing investors OrbiMed and Shanghai Hongyuan Investment Group Co., Ltd. continuing to increase their investments.The company has cumulatively raised nearly 100 million US dollars in financing so far.。

Sirius Therapeutics is an internationally innovative biotechnology company dedicated to the mission of improving human health and well-being.Focus on the Development of Next-Generation Nucleic Acid Innovative Therapies in the Field of Cardiovascular Diseases, committed to becoming a leader in revolutionizing the prevention and treatment of chronic diseases. Established in 2021, the company was incubated by globally renowned healthcare investment institutions and possesses an internationally outstanding management team. With a strategic international focus, the company leverages the talent and resource advantages in the field of small nucleic acid therapeutics from both the United States and China, establishing a global layout with the U.S. as the source of innovative R&D and China as the translational medicine hub. The company owns proprietary core technology platforms for small nucleic acid drug development and has built a robust pipeline featuring multiple products with first-in-class and best-in-class differentiation and global competitive advantages.

Dr. Qunsheng Ji, Co-founder and Chief Executive Officer/CEO of Sirius TherapeuticsFormer Vice President of WuXi AppTec and Head of the Oncology and Immunology Department; Dr. Ji has over 20 years of work and leadership experience in drug discovery and translational science. Prior to this, Dr. Qunsheng Ji served as the Head of Bioscience at AstraZeneca’s China Innovation Center. Established in Shanghai in 2007, the center benefited significantly from Dr. Ji's role as one of its early pioneers in terms of development positioning and business expansion. He was not only responsible for nearly 20 new drug R&D project pipelines in oncology and metabolic diseases at AstraZeneca, but as Director of Translational Science, he also oversaw innovative drug translational science for both global and Chinese regions. Before joining AstraZeneca, Dr. Ji worked at OSI and ONYX Biopharmaceuticals in the United States, where he led and developed multiple oncology drug projects as a program director.

Source: Sirius Therapeutics, Publicly Available Information